Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-27 |
2024-03 |
-2.54 |
N/A |
N/A |
N/A |
2024-03-29 |
2023-12 |
-3.1 |
N/A |
N/A |
N/A |
2023-11-14 |
2023-09 |
-4.4 |
-5.2 |
-0.8 |
-18.18% |
2023-11-14 |
2023-09 |
-4.4 |
N/A |
N/A |
N/A |
2023-08-21 |
2023-06 |
-4.8 |
-6 |
-1.2 |
-25.00% |
2023-08-21 |
2023-06 |
-4.8 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-01-29 |
Dawson James |
Upgrade |
|
Buy |
2018-09-13 |
Maxim Group |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2023-02-16 |
BERGER MARK STANLEY |
Officer |
245.00K |
Stock Award(Grant) |
2023-02-16 |
CONFER RYAN M. |
Chief Financial Officer |
435.50K |
Stock Award(Grant) |
2023-02-16 |
KUMAR HERMANT |
Chief Technology Officer |
200.00K |
Stock Award(Grant) |
2023-06-26 |
LONGNECKER BRENT MICHAEL |
Director |
158.79K |
Stock Award(Grant) |
2023-06-26 |
MORENO TOSCANO JOSE ANTONIO |
Director |
123.80K |
Stock Award(Grant) |
2018-03-28 |
NANCE CHRISTY MALLINSON |
Beneficial Owner of more than 10% of a Class of Security |
3.01M |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
1.83M |
1.73M |
3.07% |
2023-06-29 |
Blackrock Inc. |
456.36K |
432.90K |
0.77% |
2023-06-29 |
Geode Capital Management, LLC |
447.21K |
424.22K |
0.75% |
2023-06-29 |
State Street Corporation |
172.44K |
163.57K |
0.29% |
2023-06-29 |
Rockefeller Capital Management L.p. |
150.00K |
142.29K |
0.25% |
2023-06-29 |
Cypress Capital, LLC |
100.00K |
94.86K |
0.17% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
1.13M |
1.07M |
1.90% |
2023-06-29 |
Vanguard Extended Market Index Fund |
598.97K |
568.18K |
1.01% |
2023-05-30 |
Fidelity Extended Market Index Fund |
246.68K |
212.44K |
0.42% |
2023-05-30 |
Fidelity Total Market Index Fund |
68.09K |
58.64K |
0.11% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
54.50K |
46.93K |
0.09% |
2023-06-29 |
Vanguard Balanced Index Fund |
54.20K |
51.41K |
0.09% |
Split |
Date |
1 : 40 |
2024-02-02 |